What is FluidAI?
FluidAI operates at the intersection of medical technology and artificial intelligence, focusing on the critical surgical care journey. The company specializes in developing intelligent platforms that synthesize data from medical devices and software to provide clinicians with real-time, actionable insights. By addressing the complexities of post-operative monitoring and clinical decision-making, FluidAI aims to enhance patient outcomes and improve the operational efficiency of healthcare providers. Its market position is defined by a commitment to reducing surgical complications through high-fidelity data analysis, positioning the firm as a vital contributor to the digital transformation of hospital environments.
How much funding has FluidAI raised?
FluidAI has raised a total of $18.4M across 3 funding rounds:
Series A
$15M
Other Financing Round
$1.4M
Other Financing Round
$2M
Series A (2023): $15M with participation from Boutique Venture Partners, Graphene Ventures, and SOSV
Other Financing Round (2024): $1.4M led by Government of Ontario
Other Financing Round (2025): $2M supported by Government of Canada and FedDev Ontario
Key Investors in FluidAI
Boutique Venture Partners
A venture capital firm based in Palo Alto, California, specializing in early-stage investments in the healthcare and life sciences sectors.
Graphene Ventures
A venture capital firm that focuses on early-stage technology companies in the enterprise software and consumer technology sectors.
SOSV
A multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
What's next for FluidAI?
With the recent influx of capital, FluidAI is well-positioned to scale its technological infrastructure and expand its footprint within the global healthcare market. The strategic focus will likely shift toward deepening the integration of its AI-driven platforms into existing hospital workflows, thereby solidifying its value proposition for healthcare systems. As the company moves into this next phase of growth, the emphasis will remain on clinical validation and the expansion of its intellectual property portfolio. By leveraging both private sector expertise and public support, FluidAI is poised to set new standards for efficiency and safety in surgical care, ultimately driving long-term value for stakeholders and patients alike.
See full FluidAI company page
